[The use of a new balsamic expectorant in bronchopulmonary pathology in children].
The therapeutic effectiveness of a new antiinflammatory-expectorant drug, guacetisal (Broncaspin) has been compared with that of a well known mucolytic, bromexine, already available for therapy, in the paediatric suspension formula. The study was carried out on 26 children in the 1st Paediatrics clinic of Milan University. The children were suffering from inflammation of the respiratory apparatus. It is concluded that the new drug possesses greated clinical effectiveness.
D001241:Aspirin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001964:Bromhexine / Q000627:therapeutic use*; D001991:Bronchitis / Q000188:drug therapy*; D001996:Bronchopneumonia / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D006801:Humans; D014136:Tracheitis / Q000188:drug therapy
D001964:Bromhexine; D001241:Aspirin; C023557:guacetisal
Osservazioni sull'impiego di un nuovo espettorante balsamico nella patologia broncopolmonare del bambino.